Demerol (meperidine) is still technically available by prescription in the United States, but its use has dropped dramatically and continues to decline. Between 2010 and 2019, per capita distribution of meperidine fell by 52%, and most medical guidelines now recommend against it in favor of safer opioid alternatives. It hasn’t disappeared entirely, but it occupies a very small, shrinking corner of modern pain management.
Why Demerol Fell Out of Favor
Demerol was approved by the FDA in 1942 and spent decades as one of the most widely prescribed opioid painkillers in American hospitals. The shift began in 1984, when the death of 18-year-old Libby Zion in a New York hospital prompted closer scrutiny of the drug’s safety profile. What clinicians discovered over the following years was a serious problem baked into the drug’s chemistry.
When your body breaks down meperidine, it produces a byproduct called normeperidine. This byproduct is toxic to the nervous system. It can cause tremors, agitation, confusion, delirium, and seizures. Unlike the pain-relieving effects of the drug itself, which wear off in a few hours, normeperidine lingers in the body for 15 to 20 hours and builds up with repeated doses. People with kidney problems are especially vulnerable because they can’t clear it efficiently, but even healthy patients can accumulate dangerous levels with regular use.
The World Health Organization removed meperidine from its list of essential medicines in 2003, a clear signal from the global medical community. The Institute for Safe Medication Practices now advises against using it in older adults specifically because of this toxic byproduct. And the 2023 American Geriatrics Society Beers Criteria, a widely used guide for prescribing in older patients, calls meperidine ineffective at commonly used oral doses and flags it as carrying a higher risk of neurotoxicity and delirium compared to other opioids.
How It Compares to Other Pain Medications
Part of the reason Demerol has been so easy to replace is that it simply isn’t very good at its primary job. Studies comparing meperidine to morphine in acute pain settings have consistently found that morphine provides better pain control. In one study of patients using patient-controlled pumps after surgery, those receiving morphine reported significantly lower pain scores than those on meperidine. Other research has concluded that meperidine can only manage mild pain compared to what morphine handles, which raises an obvious question: why accept the extra risks for less relief?
Its duration of action is also shorter than morphine’s, meaning patients need more frequent doses. More frequent dosing means more normeperidine accumulation, which circles back to the neurotoxicity problem. For most types of acute pain, hospitals now stock morphine, hydromorphone, or fentanyl as standard options, all of which are more effective and don’t produce a toxic metabolite.
Where Demerol Is Still Used
The one clinical niche where Demerol has genuinely held on is treating post-anesthesia shivering. After surgery, many patients experience uncontrollable shaking as their body temperature recovers from anesthesia. Meperidine is unusually effective at stopping this. Research has shown that it suppresses shivering through a mechanism that goes beyond its painkilling properties. When compared to other opioids at equivalent pain-relieving doses, meperidine inhibits shivering significantly better than expected, suggesting it acts on temperature regulation pathways that other opioids don’t affect as strongly.
For this specific use, the drug is given as a single low dose, which avoids the normeperidine buildup that makes repeated dosing dangerous. This is why you might still encounter Demerol in a recovery room even though it has largely vanished from pain management protocols.
Dangerous Drug Interactions
Beyond normeperidine toxicity, Demerol carries interaction risks that make it particularly hazardous in a medical landscape where so many patients take antidepressants. Meperidine can trigger serotonin syndrome, a potentially fatal condition involving dangerously high body temperature, rapid heart rate, agitation, and seizures, when combined with drugs that raise serotonin levels. This includes SSRIs like fluoxetine and sertraline, SNRIs like venlafaxine, tricyclic antidepressants, triptans used for migraines, and even some muscle relaxants.
The interaction with a class of older antidepressants called MAO inhibitors is especially severe. Even a standard therapeutic dose of meperidine given to someone who has taken an MAOI within the past 14 days can cause coma, respiratory failure, and death. This combination is absolutely contraindicated. Since millions of Americans take some form of antidepressant, this interaction profile alone makes Demerol riskier to prescribe than alternatives that don’t carry the same serotonin-related dangers.
Like all opioids, it also compounds the sedating effects of benzodiazepines, alcohol, sleep medications, and other nervous system depressants, increasing the risk of fatal respiratory depression.
A Concerning Pattern Among Remaining Users
One troubling finding is that even as overall meperidine prescribing has declined, the prescriptions that remain tend to involve higher doses. Research has found that among older adults still receiving meperidine, many prescriptions exceed recommended safety limits. This suggests that the patients still getting Demerol may actually be at greater risk than the broader population of patients who received it when it was more common, a pattern that safety advocates have flagged as a lingering problem even as the drug fades from routine use.
Many hospitals have removed meperidine from their formularies entirely or restricted it to specific approved uses like post-operative shivering. Others keep it available but require special justification before a physician can order it. The trajectory is clear: Demerol is not formally banned, but the medical community has largely moved on, and its remaining footprint continues to shrink.